Merck, Inc.
🇵🇭Philippines
Subcutaneous Golimumab (GLM) Plus DMARDs for Rheumatoid Arthritis, Followed by Intravenous/Subcutaneous GLM Strategy (P06129 AM2)
Phase 3
Completed
- Conditions
- Arthritis, Rheumatoid
- Interventions
- Biological: SC golimumabBiological: IV golimumab
- First Posted Date
- 2009-09-11
- Last Posted Date
- 2017-04-13
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 3366
- Registration Number
- NCT00975130
ProQuad™ Versus M-M-R II™ and VARIVAX™ in Healthy Children (V221-009)(COMPLETED)
Phase 3
Completed
- Conditions
- MumpsMeaslesVaricellaRubella
- Interventions
- Biological: Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live
- First Posted Date
- 2009-09-11
- Last Posted Date
- 2015-10-06
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 480
- Registration Number
- NCT00975507
Bioequivalence of Two Formulations of Ondansetron in Healthy Adults (0869-106)
Phase 1
Completed
- Conditions
- Chemotherapy-Induced Nausea and Vomiting
- Interventions
- First Posted Date
- 2009-09-07
- Last Posted Date
- 2015-08-19
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 45
- Registration Number
- NCT00972595
Biomarkers of Prednisolone Treatment (P05888)
Not Applicable
Completed
- Conditions
- Insulin ResistanceHyperglycemiaGlucose Intolerance
- Interventions
- Drug: PlaceboDrug: Prednisolone
- First Posted Date
- 2009-09-04
- Last Posted Date
- 2015-05-22
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 72
- Registration Number
- NCT00971724
A Bioequivalence Study of 3 Formulations of Ondansetron in Healthy Adults (0869-095)(COMPLETED)
Phase 1
Completed
- Conditions
- Chemotherapy-Induced Nausea and Vomiting
- First Posted Date
- 2009-09-04
- Last Posted Date
- 2016-09-14
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 12
- Registration Number
- NCT00971633
Pharmacokinetics and Pharmacodynamics of MK-8245 in Participants With Type 2 Diabetes (MK-8245-012)
- First Posted Date
- 2009-09-04
- Last Posted Date
- 2018-09-10
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 56
- Registration Number
- NCT00972322
Comparative Study of Rocuronium With Vecuronium (Study 71101)(COMPLETED)
Phase 3
Completed
- Conditions
- Anesthesia
- Interventions
- First Posted Date
- 2009-09-02
- Last Posted Date
- 2015-04-17
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 90
- Registration Number
- NCT00970762
A Study to Investigate Biomarkers of Skin Androgenization Following Testosterone Administration (0000-015)(COMPLETED).
- First Posted Date
- 2009-09-01
- Last Posted Date
- 2014-09-04
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 30
- Registration Number
- NCT00969163
A Study of MK2578 in Patients With Chronic Kidney Disease Who Are Not on Dialysis (2578-002)
Phase 2
Terminated
- Conditions
- AnemiaChronic Kidney Disease
- Interventions
- Drug: MK2578
- First Posted Date
- 2009-08-31
- Last Posted Date
- 2015-11-01
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 7
- Registration Number
- NCT00968617
Bioequivalence of Two Tablet Forms of MK0974 (0974-045)
Phase 1
Completed
- Conditions
- Migraine
- Interventions
- Drug: MK0974 Ethanolate formulation
- First Posted Date
- 2009-08-26
- Last Posted Date
- 2015-07-07
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 36
- Registration Number
- NCT00965887
© Copyright 2025. All Rights Reserved by MedPath